Sophia Genetics Sa · NASDAQ:SOPH
Sophia Genetics Sa — J.P. Morgan Healthcare Conference 2022
24 slides from Sophia Genetics Sa's conference presentation, Jan 10, 2022
Slide 1: Democratizing Data-Driven Medicine Together
Democratizing Data - Driven Medicine Together Dr. Jurgi Camblong, Co - Founder & CEO J.P. Morgan Healthcare Conference - January 11, 2022
Slide 2: Cautionary Notices
This presentation contains statements that constitute forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and techno
Slide 3: An unprecedented opportunity to create a wiser and more sustainable healthcare system
We believe there is an unprecedented opportunity to create a wiser and more sustainable healthcare system SOPHiA Σοφία SOF - EE’ - AH : WISDOM
Slide 4: A Global, Leading Health Tech Company Pioneering the Data-Driven Medicine Revolution
of Employees Hold PhDs (1) 2011 500+ Year Founded Employees Globally (1) G E N E VA BO S T O N Headquarters 70+ Countries (1) 30 % 790+ Hospitals, Labs & BioPharma Customers (1) A Global, Leading Health Tech Company Pioneering The Data - Driven Medicine Revolution : SOPH 1. As of December 31, 2021
Slide 5: SOPHiA's Distinguished Team of Industry Leaders
SOPHiA’s Distinguished Team of Industry Leaders The Diverse and Innovative Force Behind Our Company Lara Hashimoto Chief Business Officer Ross Muken Chief Financial Officer Dr. Jurgi Camblong CEO & Co - Founder Melissa Finocchio Chief Regulatory Officer Abhi Verma Chief Technology Officer Daan Van W
Slide 6: Healthcare's Challenging Ecosystem
Healthcare’s Challenging Ecosystem Non - Standardized Methods of Data Generation Lead to Data Silos
Slide 7: Our Vision to Deliver a Decentralized Solution
Our Vision to Deliver a Decentralized Solution Enhancing Patient Care, Diagnosis and Drug Development Today To m o rr o w
Slide 8: The SOPHiA DDM Platform
• Leverages AI to standardize complex multimodal data • Improves and scales as more data is analyzed • Amplifies network effects • Designed to be safe and secure The SOPHiA DDM TM Platform Our Cloud Native Consumption - Based Platform Developed to Unlock Data Silos and Allow Healthcare Professionals
Slide 9: Adaptable and Scalable For Data-Driven Clinical Insights
Adaptable and Scalable For Data - Driven Clinical Insights Enabled to compute more data volume, support additional data modalities and deploy new applications and functionalities
Slide 10: Potential Applications Span the Oncology Continuum of Care
Potential Applications Span the Oncology Continuum of Care Genomics impact in other categories offers significant opportunity Genomics Germline Genomics Somatic Radiomics Somatic S c r ee n i n g Early De t e c t i o n Di a g n o s i s Therapy Se l e c t i o n Monitoring Cl i n i c a l Trials
Slide 11: One Global, Collaborative Platform Supporting Clinical and BioPharma Solutions
One Global, Collaborative Platform Supporting Clinical and BioPharma Solutions Translates data into actionable insights to support clinical experts in their fight against cancers and inherited diseases Revolutionizes drug discovery, clinical development and commercialization of new drugs
Slide 12: Robust Body of Real-World Evidence
Robust Body of Real - World Evidence Momentum to Drive Accelerated Market Adoption Ge n o m i c s Radiomics Multimodal 300+ Peer - Reviewed Publications (1) Peer - Reviewed Publications 127 2021 91 2020 61 2019 28 2018 1. As of December 31, 2021
Slide 13: DEEP-Lung-IV Multimodal Clinical Study
DEEP - Lung - IV Multimodal Clinical Study Study Outline Multicenter observational study allowing analysis of the aggregation of multimodal data associated with the response to treatment and prognosis of patients with metastatic non - small cell lung cancer Aims to enroll 4,000 patients from approx.
Slide 14: Introducing CarePath: From Data to Insights to Data-Driven Medicine
Introducing CarePath: From Data to Insights to Data - Driven Medicine Transforming Clinical Intelligence and SOPHiA’s Long - Term Opportunity Set More informed and evidence - based clinical decision making More responsive and patient - centric care Predictive and personalized medicine
Slide 15: Better Together: Leveraging Strategic Partnerships
Better Together Leveraging Strategic Partnerships to Solve Unmet Healthcare Needs C o m bi ne d with Cloud - Based platform Standardize, compute and analyze multimodal health data across hospitals and labs Cloud & On - Prem Analytics Advanced visualization of radiomic data and the versatility of the
Slide 16: Continual Enhanced Efficiency Driven by Powerful Network Effects
Continual Enhanced Efficiency Driven by Powerful Network Effects More Raw Digital Health Data Uploaded More Analyses Pe r f o r m e d More Patients Benefit From Better Care Through Data - Driven Medicine More Anonymized Statistical Data Insights Accessed New Healthcare Institutions Ho sp i t a l s L
Slide 17: This is Just The Beginning for SOPHiA
This is Just The Beginning for SOPHiA Market Leader with ~$35bn TAM and Growing ~$35 Billion Total Addressable Market ~$21 Billion Clinical Market ~$14 Billion BioPharma Market
Slide 18: Platform Analysis Volume At All-Time Highs
Platform Analysis Volume At All - Time Highs Record Consumption Despite Market Challenges 9k 11k 11k 25k 26k 16k 17k 19k 19k 29k 29k 34k 36k 40k 43k 45k 45k 31k 44k 41k 53k 66k 63k 62k Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2016 2017 2018 2019 2020 2021 ~32% Decline
Slide 19: Our Land and Expand Revenue Build
Our Land and Expand Revenue Build A Hallmark Of Our Growth Algorithm Steady growth is fueled by a balanced mix of drivers, de - risking reliance on a singular strategy
Slide 20: Strategic Pillars For Long-Term Success
Strategic Pillars For Long - Term Success Committed to Attractive Sustainable Growth and Operational Excellence Build Pa rt n e r s hip s Expand Menu of Offerings Increase Usage of Network Extend Network Size Excel Op e r a t i o na ll y Develop BioPharma Market
Slide 21: Our Progress: 2021 Highlights
Our Progress: 2021 Highlights A Milestone Year of Growth and Accomplishments $ 263 mm gross proceeds raised through our IPO & concurrent private placement from GE Healthcare ~140% net dollar retention (vs. 118% avg. of top 50+ cloud companies) <1% customer churn 30+ new products launched including H
Slide 22: Looking Ahead: Initiating 2022 Revenue Guidance
Looking Ahead: Initiating 2022 Revenue Guidance Continued Strong Momentum Expected 16 Q4 2021 New Logos Onboarded $51.5mm – $54.0mm Projected Total 2022 Revenue Range ~66 k 240 k + Q4 2021 Analysis Volume 2021 Analysis Volume
Slide 23: Thank You
THANKYOU 2; SOpHiA.
Slide 24: Q&A
Q&A Ross Muken Chief Financial Officer Dr. Jurgi Camblong CEO & Co - Founder
SOPHiA GENETICS — J.P. Morgan Healthcare Conference 2022 on 6ix